BCHE and Alzheimer disease: The only AD treatments approved by the U.S. Food and Drug Administration (USFDA) include the cholinesterase inhibitors donepezil, galantamine, and rivastigmine; they showed, however, only limited beneficial effects in clinical trials and had gastrointestinal side-effects.